Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666037 | 0.77 | KDM4E (0.36) | TRPA1KDM4ELMNATDP1 | |
| SCHEMBL31083336 | 0.70 | TRPA1 (0.42) | TRPA1KDM4ELMNATDP1 | |
| SCHEMBL20499 | 0.67 | TRPA1 (0.43) | TRPA1 | |
| SCHEMBL2493361 | 0.66 | — | — | |
| SCHEMBL23573692 | 0.64 | TRPA1 (0.46) | TRPA1KDM4ELMNATDP1 | |
| SCHEMBL23573691 | 0.64 | TRPA1 (0.46) | TRPA1KDM4ELMNATDP1 | |
| SCHEMBL3092641 | 0.64 | TRPA1 (0.41) | TRPA1KDM4ELMNATDP1 | |
| SCHEMBL244607 | 0.64 | TRPA1 (0.41) | TRPA1 | |
| SCHEMBL29800306 | 0.64 | TRPA1 (0.41) | TRPA1 | |
| Hydrochloric Acid SCHEMBL8480734 | 0.62 | TRPA1 (0.39) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 687 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562946-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2005-08-17 | — | — | EP | claimed |
| WO-2004041820-A1 | NOVEL XANTHINE DERIVATIVES, THE PRODUCTION AND THE USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-21 | — | — | WO | claimed |
| US-5637590-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-10 | — | — | US | claimed |
| US-5567709-A | IMMUNOSUPPRESSANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-10-22 | — | — | US | claimed |
| US-5559112-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-5559119-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | claimed |
| US-5541191-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-5541192-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-30 | — | — | US | claimed |
| US-5532355-A | IMMUNOSUPPRESSANTS FOR ORGAN TRANSPLANTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-07-02 | — | — | US | claimed |
| US-5519031-A | TREATMENT OF RESTENOSIS, IMMUNOSUPPRESIVE AGENTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES OR ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-21 | — | — | US | claimed |
| US-5516780-A | IMMUNOSUPPRESSIVE, ANTIINFLAMMATORY, ANTIFUNGAL AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-05-14 | — | — | US | claimed |
| US-5508286-A | Rapamycin amidino carbamates | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | claimed |
| US-5463048-A | Immunosuppressive, antiinflammatory, antifungal, antitumor, antiproliferative agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-10-31 | — | — | US | claimed |
| US-5434260-A | Treating transplantation rejection in mammals | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-07-18 | — | — | US | claimed |
| US-5385909-A | Heterocyclic esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| US-5385908-A | Hindered esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | claimed |
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| US-5385909-A | Heterocyclic esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
| US-5385908-A | Hindered esters of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | TRPA1 4885/4885KDM4E 1013/4885LMNA 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.